Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Fancy who wrote (4749)	7/6/1998 11:30:00 AM
From: Bhag Karamchandani	Respond to of 6136

Steve: Thanks. Your prolific contributions to the TBR thread make it among the most comprehensive threads to browse on SI. Now about AGPH: So far there have been few insider sales below current prices. Neither Remune nor AG3340 coverage has played to improve AGPH stock price. Only time will tell if these moves by AGPH were strategic from an investment perspective or merely expensive yet ineffective window dressing. In the case of AG 3340, we may not have to wait beyond six months (?). I do believe that it would help AGPH enormously if AG 3340 was approved - even if it offered a limited opportunity in terms of product life duration and revenues.